Fig. 5From: Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysisForest plot of CGRP mAb vs. placebo for all types of adverse events. The estimated pooled RR was 1.01 (95% CI, 0.95 to 1.07) without statistical significance (P > 0.05). There was low heterogeneity among the studies (I2 = 24%). CI confidence interval, RR risk ratioBack to article page